Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL

Cytokine and Growth Factor Reviews

Volumn 8, Issue 1, 1997, Pages 63-79

  Sattler, Martin ^a   Salgia, Ravi ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BCR ABL; Hematopoietic growth factor; Signal transduction

Indexed keywords

BCR ABL PROTEIN; CRKL PROTEIN; HEMOPOIETIC GROWTH FACTOR; NUCLEAR PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTO-ONCOGENE PROTEIN C-CBL; RAS PROTEIN;

BIOLOGICAL MODEL; CANCER GENETICS; CELL ADHESION; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; GENE ACTIVATION; GENETICS; HEMATOPOIESIS; HUMAN; MYELOID LEUKEMIA; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0031105070     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(96)00047-0     Document Type: Short Survey

References (165)

1. Virchow R. Weisses Blut. Froiep's Notizen 1845, 36, 151.
2. Bennett JH. Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood. Edinburgh Med Surg J 1845, 64, 413-423.
3. Craigie D. Case of disease of the spleen, in which death took place in consequence of the presence of purulent matter in the blood. Edinburgh Med Surg J 1845, 64, 400-413.
4. Virchow R. Die Leukämie. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Meidinger, 1865, 190.
5. Neumann E. Uber myelogene Leukämie. Berl klin Wochenschr 1878, 15, 69-72.
6. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960, 25, 85-109.
7. Baikie. AG, Court-Brown WM, Buckton KE, et al. A possible specific chromosome abnormality in human chronic myeloid leukaemia. Nature 1960, 188, 1165-1160.
8. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243, 290-293.
9. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte macrophage. Am J Med 1977, 63, 125-130.
10. Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-ABL oncogene adjacent to a translocation breakpoint in chronic myelocytic leukaemia. Nature 1983, 306, 239-242.
11. Heisterkamp N, Stam K, Groffen J, et al. Structural organization of the Bcr gene and its role in the Ph' translocation. Nature 1985, 315, 758-760.
12. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. the chronic myelogenous leukemia-specific p210 protein is the product of the Bcr/Abl hybrid gene. Science 1986, 233, 212-214.
13. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985, 315, 550-554.
14. Fainstein E, Marcelle C, Rosner A, et al. A new fused transcript in Philadephia chromosome positive acute lymphocytic leukemia. Nature 1987, 330, 386-388.
15. Clark SS, McLaughlin J, Crist WM, et al. Unique forms of the abl tyrosine kinase distinguish Ph'-positive ALL. Science 1987, 235, 85-88.
16. Walker LC, Ganesan TS, Dhut S, et al. Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukemia. Nature 1987, 329, 851-853.
17. Chan LC, Harhi KK, Rayter SI, et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987, 325, 635-637.
18. Li FP. Epidemiology of chronic leukemia. In Wiernik PH. Canellos GP, Kyle RA, et al. eds. Neoplastic Disease of the Blood. New York, Churchill Livingstone, 1991, 7-14.
19. Canellos G. Diagnosis and treatment of chronic granuloctyic leukemia. In Wiernik PH. Canellos GP, Kyle RA, et al. eds. Neoplastic Disease of the Blood. New York, Churchill Livingstone, 1991, 61-76.
20. Verma DS, Spitzer G, Gutterman, JU, et al. Human leukocyte interferon preparation blocks granulopoietic differentiation. Blood 1979, 54, 1423-1427.
21. Talpaz M, Kantarjian HM, McCredie E, et al. Hematologic remission and cytogenetic improvement induced by recominant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986, 314, 1065-1069.
22. Bhatia R, Wayner EA, McGlave PG, Verfaillie CM. Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by corrected impaired β1 integrin receptor function. J Clin Invest 1994, 94, 384-391.
23. Kurzrock R, Guttermann JU, Talpaz M. Molecular biology of chronic leukemias. In Wiernik PH, Canellos GP, Kyle RA, et al. eds. Neoplastic Disease of the Blood. New York, Churchill Livinstone, 1991, 77-96.
24. Maru Y, Witte ON. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 1991, 67, 459-468.
25. Chuang TH, Xu X, Kaartinen V, et al. Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family. Proc Natl Acad Sci USA 1995, 92, 10,282-10,286.
26. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993, 13, 7587-7597.
27. Musacchio A, Gibson T, Rice P, et al. The PH domain: a common piece in the structural patchwork of signalling proteins. [Review]. Trends Biochem Sci 1993, 18, 343-348.
28. Voncken JV, van Schaick H, Kaartinen V, et al. Increased neutrophil respiratory burst in bcr-null mutants. Cell 1995, 80, 719-728.
29. Daley GQ, McLaughlin J, Witte ON, Baltimore D. The CML-specific p210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science 1987, 237, 532-535.
30. Daley GQ, Baltimore D. Transformation of an interleukin-3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 BCR/ABL protein. Proc Natl Acad Sci USA 1988, 85, 9312-9316.
31. Golub TR, Goga A, Barker FG, Afar D, Mclaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG. Oligomerization of the Abl tyrosine kinase by the Ets protein Tel in human leukemia. Mol Cell Biol 1996, 16, 4107-4116.
32. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993, 75, 175-185.
33. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994, 13, 764-773.
34. Afar DE, Goga A, McLaughlin J, et al. Differential complementation of Bcr-Abl point mutants with c-Myc. Science 1994, 264, 424-426.
35. Wang JY, Ledley F, Goff S, et al. The mouse c-abl locus: molecular cloning and characterization. Cell 1984, 36, 349-356.
36. ml mutation show poor viability and depletion of selected B and T cell populations. Cell 1991, 65, 1165-1175.
37. Tybulewiz VL, Crawford CE, Jackson PK, et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991, 65, 1153-1163.
38. Wen ST, Jackson PK, Van Etten RA. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J 1996, 15, 1583-1595.
39. McWhirter J, Wang J. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 1993, 12, 1533-1546.
40. Van Etten R, Jackson P, Baltimore D, et al. The COOH terminus of the c-Abl tyrosine kinase contains distinct F-and G-actin binding domains with bundling activity. J Cell Biol 1994, 124, 325-340.
41. Kharbanda S, Ren R, Pandey P, et al. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 1995, 376, 785-788.
42. Welch PJ, Wang JT. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 1993, 75, 779-790.
43. Yuan ZM, Huang YY, Whang Y, et al. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 1996, 382, 272-274.
44. Wetzler M, Talpaz M, Van Etten R, et al. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 1993, 92, 1925-1939.
45. McWhirter JR, Wang JY. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadephia chromosome-positive human leukemias. EMBOJ 1993, 12, 1533-1546.
46. Renshaw MW, Mcwhirter JR, Wang J. The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement of proliferation. Mol Cell Biol 1995, 15, 1286-1293.
47. McWhirter J, Wang J. Activation of tyrosine kinase and microfilament-binding fucntions of c-Abl by Bcr sequences in Bcr Abl fusion proteins. Mol Cell Biol 1991, 11, 1553-1565.
48. Jackson PK, Paskind M, Baltimore D. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl. Oncogene 1993, 8, 1943-1956.
49. Pendergast AM, Muller AJ, Havlik MH, et al. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci USA 1991, 88, 5927-5931.
50. Maru Y, Witte ON, Shibuya M. Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence. FEBS Letts 1996, 379, 244-246.
51. Anderson SM, Mladenovic J. The BCR-ABL oncogene requires both kinase activity and Src-homology 2 domain to induce cytokine secretion. Blood 1996, 87, 238-244.
52. Ilaria RL, Vanetten RA. The SH2 domain of p210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood 1995, 86, 3897-3904.
53. Oda T, Tamura S, Matsuguchi T, et al. The SH2 domain of Abl is not required for factor-independent growth induced by Bcr-Abl in a murine myeloid cell line. Leukemia 1995, 9, 295-301.
54. Goga A, McLaughlin J, Afar DE, et al. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 1995, 82, 981-988.
55. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 1995, 15, 5531-5541.
56. Pendergast AM, Gishizky ML, Havlik MH, Witte ON. SH1 domain autophosphorylation of p210 BCR ABL is required for transformation but not growth factor independence. Molec Cell Biol 1993, 13, 1728-1736.
57. Druker B, Okuda K, Matulonis U, et al. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood 1992, 79, 2215-2220.
58. Gishizky ML, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by BCR ABL in vitro. Science 1992, 256, 836-839.
59. Bedi A, Griffin CA, Barber JP, et al. Growth factor-mediated terminal differentiation of chronic myeloid leukemia. Can Res 1994, 54, 5535-5538.
60. Bedi A, Zehnbauer BA, Barber JP, et al. Inhibition of apoptosis by Bcr-Abl in chronic myeloid leukemia. Blood 1994, 83, 2038-2044.
61. Verfaillie CM, McCarthy JB, McGlave PH. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. J Clin Invest 1992, 90, 1232-1241.
62. Gordon MY, Dowding CR, Riley GP, et al. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987, 328, 342-344.
63. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. [Review]. Science 1995, 268, 233-239.
64. Rosales C, Juliano RL. Signal transduction by cell adhesion receptors in leukocytes. [Review]. J Leukoc Biol 1995, 57, 189-198.
65. Schwartz MA, Schaller MD, Ginsberg MH. Iniegrins -Emerging paradigms of signal tranduction [Review]. Ann Rev Cell Dev Biol, 11, 549-599.
66. Levesque JP, Leavesley DI, Niutta S, et al. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med 1995, 181, 1805-1815.
67. Luna E. Molecular links between the cytoskeleton and membranes. Curr Opin Cell Biol 1991, 3, 120-126.
68. Manie SN, Sattler M, Astier M, et al. Tyrosine phosphorylation of the product of the c-cbl protooncogene is induced after integrin stimulation. Exp Hematol 1997, 25, 45-50.
69. Sugahara H, Kanakura Y, Furitsu T, et al. Induction of programmed cell death in human hematopoietic cell lines by fibronectin via its interaction with very late antigen 5. J Exp Med 1994, 179, 1757-1766.
70. Kawaishi K, Kimura A, Katoh O, et al. Decreased I-selectin expression in cd34-positive cells from patients with chronic myelocytic leukaemia. Br J Haematol 1996, 93, 367-374.
71. Ghaffari S, Dougherty GJ, Lansdorp PM, et al. Differentiation-associated changes in CD44 isoform expression during normal hematopoiesis and their alteration in chronic myeloid leukemia. Blood 1995, 86, 2976-2985.
72. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996, 87, 3883-3891.
73. Salgia R, Avraham S, Pisick E, et al. The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem 1996, 271, 3122-31226.
74. Salgia R, Li JE, Curry E, Pisick E, et al. Transformation of hematopoietic cells by BCR/ABL is associated with enhanced motility. Blood (Suppl.) 1996, 88, 675a.
75. Salgia R, Brunkhorst B, Pisick E, et al. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 1995, 11, 1149-1155.
76. Hill A, Naama HA, Calvano Se, Daly JM. The effect of granulocyte-macrophage colony-stimulating factor on myeloid cells and its clinical applications [Review]. J Leukoc Biol 1995, 58, 634-642.
77. Kharbanda S, Saleem A, Yuan Z, et al. Stimulation of human monocytes with macrophage colony-stimulating factor induces a Grb2-mediated association of the focal adhesion kinase pp125FAK and dynamin. Proc Natl Acad Sci USA 1995, 92, 6132-6136.
78. Denichilo MO, Yamada KM. Integrin alpha(v)beta(5)-dependent serine phosphorylation of paxillin in cultured human macrophages adherent to vitronectin. J Biol Chem 1996, 271, 11,016-11,022.
79. Salgia R, Li JL, Lo SH, et al. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by p210(bcr abl). J Biol Chem 1995, 270, 5039-5047.
80. Denhardt DT. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell - the potential for multiplex signalling [Review]. Biochem J 1996, 318, 729-747.
81. Bonfini L, Migliaccio E, Pelicci G, et al. Not all SHC roads lead to Ras [Review]. Trends Biochem Sci 1996, 21, 257-261.
82. Macara IG, Lounsbury KM, Richards SA, et al. The Ras superfamily of GTPases [Review]. FASEB J 1996, 10, 625-630.
83. Marshall MS. Ras target proteins in eukayotic cells [Review]. FASEB J 1995, 9, 1311-1318.
84. Terada K, Kaziro Y, Satoh T. Ras is not required for the interleukin 3-induced proliferation of a mouse pro-B cell line, BaF3. J Biol Chem 1995, 270, 27,780-27,886.
85. Sakai N, Ogiso Y, Fujita H, et al. Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells. Exp Cell Res 1994, 215, 131-136.
86. Skorski T, Kanakaraj P, Ku DH, et al. Negative regulation of p120GAP GTPase promoting activity by p210Bcr Abl - implication for ras-dependant Philadelphia chromosome positive cell growth. J Exp Med 1994, 179, 1855-1865.
87. Gishizky ML, Cortez D, Pendergast AM. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci USA 1995, 92, 10,889-10,893.
88. Langdon WY, Blake TJ. The human CBL oncogene. Curr Top Microbiol Immunol 1990, 166, 159-164.
89. Maria GL, Dikic I, Batzer AG, et al. Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation. J Biol Chem 1995, 270, 20,242-20,245.
90. Blake TJ, Heath KG, Langdon WY. The truncation that generated the v-Cbl oncogene reveals an ability for nuclear transport, DNA binding and acute transformation. EMBO J 1993, 12, 2017-2026.
91. Blake TJ, Shapiro M, Morse HD, Langdon WY. The sequences of the human and mouse c-Cbl proto-oncogenes show v-Cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif. Oncogene 1991, 6, 653-657.
92. Langdon WY, Hartley JW, Klinken SP, et al. v-Cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc Natl Acad Sci USA 1989, 86, 1168-1172.
93. Langdon WY, Hartley JW, Klinken SP, et al. Molecular characterization of a transforming retrovirus involved in pre-B cell lymphomas. Curr Top Microbiol Immunol 1988, 141, 27-30.
94. Keane MM, Rivero-Lezcano OM, Mitchell JA, et al. Cloning and characterization of Cbl-b: A SH3 binding protein with homology to the c-Cbl proto-oncogene. Oncogene 1995, 10, 2367-2377.
95. Yoon CH, Lee J, Jongeward GD, Sternberg PW. Similarities to Sli-1, a regulator of vulval development in C. elegans, to the mammalian proto-oncogene c-Cbl. Science 1995, 269, 1102-1105.
96. Tanaka S, Amling M, Neff L, et al. C-cbl is downstream of c-src in a signalling pathway necessary for bone resorption. Nature 1996, 383, 528-531.
97. Salgia R, Sattler M, Pisick E, et al. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protoncogene product p 120c-Cbl. Exp Hematol 1996, 24, 310-313.
98. Donovan JA, Wange RL, Langdon WY, Samelson LE. The protein product of the c-Cbl protooncogene is the 120-kDa tyrosine-phosphorylated protein in jurkat cells activated via the T cell antigen receptor. J Biol Chem 1994, 269, 22,921-22,924.
99. Liu YC, Elly C, Yoshida H, et al. Activation-modulated association of 14-3-3 proteins with Cbl in T cells. J Biol Chem 1996, 271, 14,591-14,595.
100. Sattler M, Salgia R, Okuda K, et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 1996, 12, 839-846.
101. Fukazawa T, Reedquist KA, Trub T, et al. The SH3 domain-bindingTcell tyrosylphosphoprotein p120. Demonstration of its identify with the c-Cbl protooncogene product and in vivo complexes with Fyn, Grb2, and phosphatidylinositol 3-kinase. J Biol Chem 1995, 270, 19,141-19,150.
102. Meisner H, Conway BR, Hartley D, Czech MP. Interactions of Cbl with Grb2 and phosphatidylinositol 3′-kinase in activated Jurkat cells. Mol Cell Biol 1995, 15, 3571-3578.
103. Lupher ML, Reedquist KA, Miyake S, et al. Novel phosphototyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively ZAP-70 in T cells. J Biol Chem 1996, 271, 24,063-24,068.
104. Meisner H, Czech MP. Coupling of the proto-oncogene product c-Cbl to the epidermal growth factor receptor. J Biol Chem 1995, 270, 25,332-25,335.
105. Galisteo ML, Dikic I, Batzer AG, et al. Tyrosine phosphorylation of the c-Cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation. J Biol Chem 1995, 270, 20,242-20,245.
106. Odai H, Sasaki K, Iwamatsu A, et al. The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells. J Biol Chem 1995, 270, 10,800-10,805.
107. Sattler M, Durstin MA, Frank DA, et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol 1995, 23, 1040-1048.
108. CBI. J Biol Chem (in press).
109. Cory GO, Lovering RC, Hinshelwood S, et al. The protein product of the c-Cbl protoncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase. J Exp Med 1995, 182, 611-615.
110. Tanaka S, Neff L, Baron R, Levy JB. Tyrosine phosphorylation and translocation of the c-cbl protein after activation of tyrosine kinase signaling pathways. J Biol Chem 1995, 270, 14,347-14,351.
111. Andoniou CE, Thien CBF, Langdon WY. Tumor induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J 1994, 13, 4515-4523.
112. Siegler R, Zajdel S. Pathogenesis of Abelson-virus-induced murine leukemia. J Natl Cancer Inst 1972, 48, 189-218.
113. deJong R, ten Hoeve J, Heisterkamp N, Groffen J. CRKL is complexed with tyrosine-phosphorylated cbl in Ph-positive leukemia. J Biol Chem 1995, 270, 21,468-21,471.
114. Kapeller R, Cantley LC. Phosphatidylinositol 3-kinase. [Review]. Bioessays 1994, 16, 565-576.
115. Carpenter CL, Cantley LC. Phosphoinositide 3-kinase and the regulation of growth [Review]. Biochim Biophys Acta Rev Cancer 1996, 1288, 16.
116. Shepherd PR, Reaves BJ, Davidson HW. Phosphoinositide 3-kinase and membrane traffic [Review]. Trends Cell Biol 1996, 6, 92-97.
117. Herbst JJ, Andrews G, Contillo L, et al. Potent activation of phosphatidylinositol 3′-kinase by simple phosphotyrosine peptides derived from insulin receptor substrate 1 containing two YMXM motifs for binding SH2 domains. Biochemistry 1994, 33, 9376-9381.
118. Divecha N, Irvine RF. Phospholipid signaling. [Review]. Cell 1995, 80, 269-278.
119. Rameh LE, Chen CS, Cantley LC. Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Cell 1995, 83, 821-830.
120. Gold MR,. Duronio V, Saxena SP, et al. Multiple cytokines activate phosphatidylinositol 3-kinase in hemopoietic cells. Association of the enzyme with various tyrosine-phosphorylated proteins. J Biol Chem 1994, 269, 5403-5412.
121. Serve H, Hsu YC, Besmer P. Tyrosine residue 719 of the c-kit receptor is essential for binding of the p85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J Biol Chem 1994, 269, 6026-6030.
122. Sun XJ, Rothenberg P, Kahn CR, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991, 352, 73-77.
123. Skorski T, Kanakaraj P. Nieborowska-skorska et al. Phosphatidylinositol-3 kinase activity is regulated by bcr/abl and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995, 86, 726-736.
124. Harrisonfindik D, Susa M, Varticovski L. Association of phosphatidylinositol 3-kinase with she in chronic myelogeneous leukemia cells. Oncogene 1995, 10, 1385-1391.
125. Varticovski L, Daley GQ, Jackson P, et al. Activation of phosphatidylinositol 3-kinase in cells expressing Abl oncogene variants. Molec Cell Biol 1991, 11, 1107-1113.
126. Jain SK, Susa M, Keeler ML, et al. PI 3-kinase activation in BCR/ABL-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/ABL. Blood 1996, 88, 1542-1550.
127. Klippel A, Reinhard C, Kavanaugh WM, et al. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Molec Cell Biol 1996, 16, 4117-4127.
128. ten Hoeve J, Arlinghaus RB, Guo JQ, et al. Tyrosine phosphorlyation of Crkl in Philadelphia (+) leukemia. Blood 1994, 84, 1731-1736.
129. Oda T, Heaney C, Hagopian JR, et al. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994, 269, 22,925-22,928.
130. Nichols GL, Raines MA, Vera JC, et al. Identification of CRKL as the constitutively phosphorylated 30-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994, 84, 2912-2918.
131. deJong R, Haataja L, Voncken JW, et al. Tyrosine phosphorylation of murine crkl. Oncogene 1995, 11, 1469-1474.
132. Feller SM, Ren RB, Hanafusa H, Baltimore D. SH2 and SH3 domains as molecular adhesives - the interactions of Crk and Abl. Trends Biochem Sci 1994, 19, 453-458.
133. ten Hoeve J, Morris C, Heisterkamp N, Groffen J. Isolation and chromosomal localization of CRKL, a human Crk-like gene. Oncogene 1993, 8, 2469-2474.
134. Mayer BJ, Hanafusa H. Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation. J Virol 1990, 64, 3581-3589.
135. Matsuda M, Tanaka S, Nagata S, et al. Two species of human CRK cDNA encode proteins with distinct biological activities. Molec Cell Biol 1992, 12, 3482-3489.
136. Feller SM, Knudsen B, Hanafusa H. Cellular proteins binding to the first src homology 3 (SH3) domain of the proto-oncogene product c-crk indicate crk-specific signaling pathways. Oncogene 1995, 10, 1465-1473.
137. Andoniou CE, Thien C, Langdon WY. The two major sites of Cbl tyrosine phosphorylation in Abl-transformed cells select the Crkl SH2 domain. Oncogene 1996, 12, 1981 1989.
138. Salgia R, Pisick E, Sattler M, et al. p130CAS forms a signaling complex with the adapter protein Crkl in hematopoietic cells transformed by the Bcr Abl oncogene. J Biol Chem 1996, 271, 25,198-25,203.
139. Salgia R, Uemura N, Okuda K, et al., Crkl links p210 BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 1995, 270, 29,145-29,150.
140. ten Hoeve J, Kaartinen V, Fioretos T, et al. Cellular interactions of CRKL, and SH2-SH3 adaptor proteins. Cancer Res 1994, 54, 2563-2567.
141. Birge RB, Fajardo JE, Reichman C, et al. Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts. Molec Cell Biol 1993, 13, 4648-4656.
142. Schaller MD, Parsons JT. pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk. Molec Cell Biol 1995, 15, 2635-2645.
143. Petruzzelli L, Takami M, Herrera R. Adhesion through the interaction of lymphocyte function-associated antigen-1 with intracellular adhesion molecule-1 induces tyrosine phosphorylation of p130CAS and its association with c-CrkII. J Biol Chem 1996, 271, 7796-7801.
144. Sakai R, Iwamatsu A, Hirano N, et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. Eur Molec Biol Org J 1994, 13, 3748-3756.
145. Law SF, Estojak J, Wang BL, et al. Human enhancer of filamentation 1, a novel p130CAS-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in saccharomyces cerevisiae. Molec Cell Biol 1996, 16, 3327-3337.
146. Alexandropoulos K, Baltimore D. Coordinate activation of c-Src by SH3-and SH2-binding sites on a novel p130Cas-related protein, Sin. Genes Dev 1996, 10, 1341-1355.
147. Ishino M, Ohna T, Sasaki H, Sasaki T. Molcular cloning of a cDNA encoding a phosphoprotein, EFS, which contains a Src homology 3 domain and associates with Fyn. Oncogene 1995, 11, 2331-2338.
148. Feller SM, Knudsen B, Hanafusa. H. c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J 1994, 13, 2341-2351.
149. Ren R, Ye ZS, Baltimore D. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev 1994, 8, 783-95.
150. Senechal K, Halpern J, Sawyers CL. The Crkl adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem 1996, 271, 23,255-23,261.
151. Briscoe J, Kohlhuber F, Muller M. JAKs and STATs branch out. Trends Cell Biol 1996, 6, 336-340.
152. Ihle JN, Kerr IM. JAKs and STATs in signaling by the cytokine receptor superfamily. [Review]. Trends Genet 1995, 11, 69-74.
153. Zhang Z, Blenis J, Li HC, et al. Requirement of serine phosphorylation for formation of STAT-promotor complexes. Science 1995, 267, 1990-1994.
154. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996, 84, 443-450.
155. Mui A, Wakao H, Kinoshita T, et al. Suppression of interleukin-3-induced gene expression by a C-terminal truncated STATS role of STATS in proliferation. Eur Molec Biol Org J 1996, 15, 2425-2433.
156. Luo H, Hanratty WP, Dearolf CR. An amino acid substitution in the drosophila hop (Tum-1) JAK kinase causes leukemia-like hematopoietic defects. Eur Molec Biol Org J 1995, 14, 1412-1420.
157. Shuai K, Halpern J, tenHoeve J, et al. Constitutive activation of Stat5 by the Bcr-Abl oncogene in chronic myelogenous leukemia. Oncogene 1996, 13, 247-254.
158. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by BCR/ABL. J Exp Med 1996, 183, 811-820.
159. Holtschke T, Löhler J, Kanno Y, et al. Immunodefiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996, 87, 307-317.
160. Lees E. Cyclin dependent kinase regulation [Review]. Curr Opin Cell Biol 1995, 7, 773-780.
161. Wang JY, Knudsen ES, Welch PH. The retinoblastoma tumor suppressor protein. [Review]. Adr Cancer Res 1994, 64, 25-85.
162. Beijersbergen RL, Bernards R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins [Review]. Biochim Biophsy Acta Rev Cancer 1996, 1287, 103-120.
163. Afar DE, McLaughlin J, Sherr CJ, et al. Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci USA 1995, 92, 9540-9544.
164. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992, 70, 901-910.
165. Stewart MJ, Litz-Jackson S, Burgess GS, et al. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells. Leukemia 1995, 9, 1499-1507.